LUKA MILAS, M.D. PHD
Radiology at Holcombe Blvd, Houston, TX

6649645, Nov 18, 2003

Aug 27, 1999

09/385214

John P McKearn - St. Louis MO
Jaime L Masferrer - Ballwin MO
Luka Milas - Houston TX

Pharmacia Corporation - St. Louis MO

A61K 31415

514406, 514403

The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of radiation therapy and a cyclooxygenase-2 inhibitor.

6984619, Jan 10, 2006

Mar 13, 2000

09/523886

David J. Grdina - Naperville IL, US
Luka Milas - Houston TX, US

Arch Development Corporation - Chicago IL
Board of Regents, The University of Texas System - Austin TX

A01N 61/00, C12Q 1/00, C12Q 1/68

514 1, 435 4, 435 6

Methods and pharmaceuticals for inhibiting or preventing metastasis formation in animals, including humans, having primary tumors, through the administration of phosphorothioates including their thiol and disulfide metabolites are disclosed. These compounds stimulate angiostatin levels, inhibit matrix metalloproteinases (MMPs), and stimulate manganese superoxidase dismutase (MnSOD). Phosphorothioates, of which amifostine is an example, can be administered as a combination therapy with traditional cancer therapies, including chemotherapy, radiotherapy, surgery, immunotherapy, hormone therapy and gene-therapy. Inhibition or prevention of metastasis by phosphorothioates is independent of tumor type, including adenocarcinomas and sarcomas.

2011008, Apr 14, 2011

Apr 10, 2009

12/937241

Luka Milas - Houston TX, US

Board of Regents, The University of Texas System - Austin TX

A61K 31/5355, C12N 5/071, A61K 31/53, A61P 35/00

5142332, 435325, 514243

Provided herein is a method of radiosensitizing a tumor in a subject, which comprises administering to the subject a radiosensitizing amount of an indazolpyrrolotriazine of Formula I. Also provided herein is a method of treating a tumor in a subject, which comprises the steps of administering to the subject a radiosensitizing amount of an indazolpyrrolotriazine of Formula I, and a therapeutically effective fraction of radiation.

2009017, Jul 2, 2009

Oct 3, 2008

12/245438

James M. Tour - Bellaire TX, US
Valerie C. Moore - Houston TX, US
Jeffrey N. Myers - Bellaire TX, US
Zvonimir L. Milas - Houston TX, US
Kathy A. Mason - Houston TX, US
Luka Milas - Houston TX, US
Brandl Katherine Price - Houston TX, US
Jared L. Hudson - Hamilton VA, US
Ashley Leonard - Houston TX, US
Dmitry V. Kosynkin - Houston TX, US

William Marsh Rice University - Houston TX

A61K 38/18, A61K 31/337, A61K 47/04

514 12, 514449, 514769, 977746, 977750, 977906

Compositions comprising a plurality of functionalized carbon nanotubes and at least one type of payload molecule are provided herein. The compositions are soluble in water and PBS in some embodiments. In certain embodiments, the payload molecules are insoluble in water. Methods are described for making the compositions and administering the compositions. An extended release formulation for paclitaxel utilizing functionalized carbon nanotubes is also described.

2005011, May 26, 2005

Oct 4, 2004

10/957875

Robert Newman - Houston TX, US
Crandell Addington - San Antonio TX, US
Sachiko Nasu - Tunina, JP
Luka Milas - Houston TX, US
Shinichiro Kawabe - Osaka, JP
Uma Raju - Missouri City TX, US

Phoenix Biotechnology, Inc. - San Antonio TX
The University of Texas - Houston TX

A61K051/00, A61K031/704

424001110, 514026000, 600001000

A method for enhancing the radiosensitivity of cells through the administration of an exogenous cardiac glycoside, such as oleandrin. The magnitude of radiosensitization depends on the duration of exposure of the cells to oleandrin prior to irradiation. Treatment of cells with oleandrin increases the sensitivity of the cells to radiation-induced apoptosis. Thus, treatment with oleandrin and radiotherapy effectively lessens the proliferation of tumor cell populations.